1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid) has been researched along with melphalan in 2 studies
| Studies (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid)) | Trials (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid)) | Recent Studies (post-2010) (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid)) | Studies (melphalan) | Trials (melphalan) | Recent Studies (post-2010) (melphalan) |
|---|---|---|---|---|---|
| 25 | 4 | 8 | 8,134 | 1,351 | 1,972 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bensinger, W; Durack, LD; Eary, JF; Fritzberg, A; Rajendran, JG; Vernon, C | 1 |
| Bouchet, L; Breitz, H; Stabin, M; Wendt, R; Wessels, B | 1 |
2 trial(s) available for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid) and melphalan
| Article | Year |
|---|---|
High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow Purging; Female; Holmium; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Organophosphorus Compounds; Radioisotopes; Radiometry; Radiotherapy Dosage; Tissue Distribution | 2002 |
Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.
Topics: Antineoplastic Agents, Alkylating; Cohort Studies; Combined Modality Therapy; Holmium; Humans; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Muscle, Skeletal; Organophosphorus Compounds; Radioisotopes; Radiometry; Radiotherapy Dosage; Tissue Distribution | 2003 |